ArticleNature communications2023
HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 19 citations in OpenAlex.
- Preferential engagement of the anti-inflammatory ATP/adenosine axis by HIV vaccine candidate with V1-deleted envelope in male rhesus macaques.Cell reports. Medicine · 2026Article
- Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates.Journal of virology · 2026Article
- Sustained mucosal delivery of SAMT-247 via an intravaginal ring reduces the risk of SIVCell reports. Medicine · 2026Article
- Global Proteomics Investigation of SAMT-247 Targets: An Antiviral Thioester that Acetylates Zinc Finger Proteins.bioRxiv : the preprint server for biology · 2026Article
- Decoding miRNA-Mediated Immunoregulation in SARS-CoV-2, HBV, HIV, and HSV Infections.Genes and immunity · 2026Review
- A 3-Dimensional Bioprinted Decellularized Umbilical Cord Matrix Patch for Enhanced Storage and Delivery of Extracellular Vesicles in Diabetic Wound Healing.Research (Washington, D.C.) · 2026Article
- Friend or foe: divergent immunomodulatory effects of metabolites derived from the virucidal zinc finger inhibitor SAMT-247.Frontiers in immunology · 2026Article
- HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques.Nature communications · 2025Article
- High expression of Rex-orf-I and HBZ mRNAs and bronchiectasis in lung of HTLV-1A/C infected macaques.Nature communications · 2025Article
- BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.JCI insight · 2025Article
- In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome.Nature communications · 2025Article
- Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein.Journal of virology · 2025Article
- Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.Nature communications · 2024Article
- Article
- Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.Viruses · 2024Review
- Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.Frontiers in immunology · 2024Article
- Complex Evolutionary History With Extensive Ancestral Gene Flow in an African Primate Radiation.Molecular biology and evolution · 2023Article
- In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4Vaccines · 2023Article
- Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein.PLoS pathogens · 2023Article
- HIV vaccine candidate plus microbicide decreases SIV infection risk by more than 90.Nature microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 7 institutions in 1 country.
Massimiliano BissaAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA. massimiliano.bissa@nih.gov.ORCID 0000-0003-3455-3992
Sohyoung KimLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Veronica GalliAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Slim FouratiDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0001-6609-7587
Sarkis SarkisAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Anush ArakelyanSection on Intercellular Interactions, Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Isabela Silva de CastroAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Mohammad Arif RahmanAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-6120-8943
Saori FujiwaraLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-3531-577X
Monica VaccariAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Jeffrey A TomalkaDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
James D StamosAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Luca SchifanellaAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Giacomo GoriniAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Ramona MolesAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Anna GutowskaAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-9873-6432
Guido FerrariDivision of Surgical Sciences, Duke University School of Medicine, Durham, NC, USA.
Alexei LobanovCollaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
David C MontefioriDivision of Surgical Sciences, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-0856-6319
George W NelsonCollaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Margaret C CamCollaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Marita ChakhtouraDepartment of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.
Elias K HaddadDepartment of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.ORCID 0000-0001-6924-4300
Melvin N DosterAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
Katherine McKinnonVaccine Branch Flow Cytometry Core, National Cancer Institute, Bethesda, MD, USA.
Sophia BrownAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA.
David J VenzonBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-8990-158X
Hyoyoung Choo-WosobaBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Matthew W BreedLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD, USA.
Kristin E KilloranLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD, USA.ORCID 0000-0002-5400-1231
Joshua KramerLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD, USA.
Leonid MargolisSection on Intercellular Interactions, Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Rafick P SekalyDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-7816-4828
Gordon L HagerLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Genoveffa FranchiniAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA. franchig@mail.nih.gov.ORCID 0000-0003-2851-6589
National Cancer Institute · USNational Institutes of Health · USEmory University · USLeidos (United States) · USDrexel University · USDuke University · USTulane University · US
Funding
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MPreventive Vaccines for HIVZIABC011126 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FRANCHINI, GENOVEFFA · 2009 to 2025
$55.3MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5MChromatin Structure and Gene ExpressionZIABC005450 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HAGER, GORDON L · 2009 to 2025
$35.2MOffice of Collaborative BiostatisticsZIDSC007202 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CHOO-WOSOBA, HYOYOUNG · 2009 to 2025
$14.5MViral transmission and pathogenesis in human tissuesZIAHD008968 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI MARGOLIS, LEONID B. · 2018 to 2023
$12.2MCCR VB FACS COREZICBC010936 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCKINNON, KATHERINE · 2009 to 2025
$10.9MNIAID NIH HHS HHSN272201800004CNIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI064518NIH HHS P51 OD011104
Abstract
The development of an effective vaccine to protect against HIV acquisition will be greatly bolstered by in-depth understanding of the innate and adaptive responses to vaccination. We report here that the efficacy of DNA/ALVAC/gp120/alum vaccines, based on V2-specific antibodies mediating apoptosis of infected cells (V2-ADCC), is complemented by efferocytosis, a cyclic AMP (cAMP)-dependent antiphlogistic engulfment of apoptotic cells by CD14
Indexed as
AIDS VaccinesHIV InfectionsAnimalsAntibody-Dependent Cell CytotoxicityFemaleHIV AntibodiesHIV Envelope Protein gp120Macaca mulattaVaccinationVaccine EfficacyAIDS VaccinesHIV AntibodiesHIV Envelope Protein gp120
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.